Ashish Pradhan Email & Phone Number

South San Francisco, California, Us

South San Francisco, California, Us

Ocrelizumab (Ocervus) Strategy lead for Product Safety, Publications and Exploratory data analyses.

South San Francisco, California, Us

Basel, Baselstadt, Ch

I oversaw key aspects of the US medical affairs strategy for Gilenya (fingolimod) and parts of the neuroscience portfolio, bridging the gap between clinical development and product development and providing medical leadership to commercially led initiatives.As chair of the Gilenya (fingolimod) medical product team, I guided cross-functional stakeholders in developing and executing the medical product plan and integrated strategy for the brand, lead medical advisory boards, and drive implementation of high-value strategies for product lifecycle development and management.Other areas of impact included medical leadership at governance board meetings and oversight of brand publication activities and other KOL/advocacy initiatives.

Basel, Baselstadt, Ch

I provided medical leadership of all ongoing global safety studies for Gilenya, managing team performance and guiding multi-disciplinary trial teams to align clinical deliverables with goals and objectives to support market access and regulatory positioning. One of my goals was creating a shared sense of purpose among global trial teams, which I achieved by creating an inclusive and open team culture that integrated global, matrixed teams into a cohesive and collaborative unit. I led multiple clinical study report submissions and responses to international health authority requests and successfully raised awareness internally of study-related challenges through influence building and impactful presentations.

Basel, Baselstadt, Ch

As global medical expert for 2 worldwide Phase IV programs in multiple sclerosis, I unified cross-functional teams around clinical deliverables for US FDA and European Medicines Agency response commitments and guided scientific and medical strategy to execution.

Basel, Baselstadt, Ch

I devised a strategically critical training program to develop medical science liaisons (MSLs) and served as global medical lead for 3 ongoing phase IV studies. Additionally, I supported global HEOR initiatives comprising real world effectiveness studies and health technology assessments (HTAs), which are increasingly more crucial to the US and global health economics landscape.

New York, New York, Us

As US medical director for Tafamadis, a developmental compound for an ultra-rare, hereditary form of amyloidosis, TTR-FAP. I developed strategies to support US medical product needs and provided medical input into brand tactics. I planned and implemented US/global advisory boards, assembling expert guidance to serve as the framework for medical planning initiatives.I was a critical team member on the efficacy sub-team for our presentation to the FDA's Advisory Committee, a tremendous experience for my team and my own professional development. Additionally, I led teams in the development of medical publications and congress presentations and drove our KOL alignment efforts.

New York, New York, Us

Medical point person for co-marketed product, Rebif. I worked closely with counterparts at EMD Serono to support in-line marketing activities, ensuring alignment and compliance of communications and promotions.My impact and influence encompassed medical leadership for the development of annual medical plans, brand plans, and promotional materials. I worked in a cross-functional capacity to promote strong relationships in a challenging co-promotion environment and collaborated on the creation of operating plans for the neuroscience portfolio.

New York, New York, Us

In this role, I gained broad exposure and expertise managing health technology assessments (HTAs), recommending tactics to optimize submissions for favorable reviews by HTA bodies such as AHRQ (USA), NICE (UK), CADTH (Canada), and PBAC (Australia). I communicated our group's vision to multiple stakeholders and orchestrated medical assessment review and economic modeling efforts across multiple therapeutic areas. Through critical evaluation, we were able to effectively prioritize early-stage pipeline products utilizing EBM principles

Lawrence Township, Nj, Us

I managed alliance relationships with Sanofi-Aventis and co-led lifecycle management for Plavix (clopidogrel) to maximize the long-term potential of this blockbuster drug. Through content-area leadership, KOL management, and cross-functional collaboration with matrix teams comprising stakeholders from global clinical operations, regulatory, marketing, legal, market research, medical information, and public relations groups, we produced a high-level strategy for commercialization and post-market exclusivity of this multibillion-dollar product.In addition to medical education and KOL initiatives, I managed an active patient registry with an international cohort, REduction of Atherothrombis for Continued Health (REACH), which aimed to compile an international data set of atherothrombotic risk factors and ischemic events in the outpatient setting.

Lawrence Township, Nj, Us

Supervised team in design, development, and implementation of global health economics strategy for Pargluva (muraglitzar) - a joint venture product with Merck - and for Orencia (abatacebpt). Highlights included production of the global economic dossier and budget impact models for Pargluva and significant contributions to improving joint venture collaboration.

Lawrence Township, Nj, Us

Held dual role as Lipostat (pravastatin) brand team member and medical monitor for Pargluva. Acquired foundational experience in medical affairs, stakeholder management, and product promotions.

Pharmacoepidemiology, Health Economics, Psychopharmacology

Mbbs, Md, Medicine